A 12-week, Double-blind, Placebo-controlled Efficacy and Safety Study of Preladenant for Patients with Moderate to Severe Parkinson’s Disease.
- Ages 30 to 85
- Must have diagnosis of Idiopathic Parkinson’s Disease.
- Must currently be taking at least 1 year of ongoing therapy with Levodopa.
- Must not have any other form of Parkinson’s or cognitive impairment.
Alpine Clinical Research Center
1000 Alpine Avenue, Suite 200
Boulder, CO 80304